Business Context and Reporting Period
Company: Compass Therapeutics, Inc. (CMPX)
Filing Type: Form 8-K (Current Report)
Date: March 10, 2023
Context: The filing addresses investor concerns regarding the company's exposure to Silicon Valley Bank (SVB) following recent banking sector instability.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report is limited to a disclosure regarding the location of cash deposits.
Material Changes
No material changes to financial performance or operational status are reported in this document. The filing serves solely to clarify the company's banking relationships.
Guidance, Outlook, and Risks
Management Commentary: The Company explicitly states that it does not hold cash deposits or securities at Silicon Valley Bank.
Risks: This disclosure mitigates the risk of liquidity loss associated with the SVB situation for this specific registrant.
Key Facts for Investor Verification
- Compass Therapeutics, Inc. confirms zero exposure to Silicon Valley Bank regarding cash deposits or securities.
- The filing was signed by Neil Lerner, VP Finance, on March 10, 2023.
- Investors should refer to the company's most recent 10-K or 10-Q for detailed financial metrics, as this 8-K contains no quantitative financial data.